Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

One man's trash may be another man's treasure, but dumpster diving when investing carries risks. You have to wade through a ...

With macroeconomic uncertainty swirling, Bank of America analyst Anthony Cassamassino warns that a worst-case scenario could ...

The results exceeded Wall Street targets and pushed the U.S. drugmaker's shares up 11% in premarket trading, while dragging ...

PARIS – Amid the luxury slowdown, Hermès International showed continued strength with sales in the first quarter up 7 percent ...

Eli Lilly shares slid 8.2% last month thanks to tariff tremors and Medicare’s snub of pricey weight-loss drugs. The company’s ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and ...

Pfizer has discontinued its experimental weight-loss pill danuglipron after a trial patient experienced potential ...

Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient experienced potential drug-induced liver injury which resolved after the ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...